Pay in installments of $5.00 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 2 - Jul 7
Promo Codes Available:
For Your Every Summer RSVP, with Code: SUMMER15
Description
The U.S. Food and Drug Administration approved Novo Nordisk's oral semaglutide (Wegovy) as the first GLP 1 pill for obesity and cardiovascular risk reduction, with the company targeting an early 2026 launch. Novo FLOW Trial Shows Benefit of Semaglutide in Type 2 Diabetes and Chronic Kidney Disease: EASD 2024 EMJ If your GLP 1 shot burns or stings when you inject it WATCH THIS. Dr. Bragg breaks down exactly why it happens and the quick trick to avoid it next time. Save this revive rx pharmacy semaglutide Tirzepatide: Wanted to Lose Weight but on a tight budget. I did Semaglutide Injectable 4 mg mL Vivify Pharmaceuticals
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
4.5 ★★★★★
Based on 2188 reviews
Sort
Product Reviews
★★★★★ 5
The most well researched book about Section 230 and free speech on the Internet
Format: Hardcover
Many are calling for regulation of the tech industry. This book does an excellent job of outlining the “it’s not that simple” aspect of the debate. Some say big tech is doing too much to silence legitimate conversations and others say they are not doing enough to combat hate speech and false information.
Regardless of which side you fall on it is important to know the history and this book is a well written account. Professor Kosseff does an excellent job of both presenting the history of Section 230, but also mixing in his well reasoned opinions about how we should proceed. Most importantly posing the question of if you don’t want big tech regulating the internet, you better think long and hard about who you do want, and what that will look like.
This should be a mandatory read for any tech reporter who even utters the words “Section 230”. Thanks for the information.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on August 26, 2019
★★★★★ 5
The book that might save the internet
Format: Hardcover
The level of misunderstanding about Section 230 in media and government is astounding. All they have to do is read Kosseff's book to clear up their misunderstanding. The New York Times made a colossal mistake confusing Section 230 with the First Amendment. I hear media people all the time thinking they can't moderate comments because of Section 230 (the opposite is true). I see politicians going after Section 230 because they think it is the root of the net's problems (they are dead wrong). Section 230 is our best protection of free expression and human dignity on the net, for as Kosseff clearly explains, it is intended to enable the public conversation (by not making platforms -- including news organizations -- liable for what others do on their sites) and it is also intended to empower platforms and media companies to moderate what people do on their sites to their own standards. The law is short and clear and is vital to the future of the net and the public conversation on it.
Kosseff puts forward an excellent history of the development of legislation and case law on free expression in books, movies, and other media. He talks with the creators of Section 230 and explains their goals and motives. He outlines the debate about the law.
That debate is now reaching a critical phase in both media and Washington. Thus Kosseff's book is a document of urgent importance. I wish some rich person would come along to buy every member of Congress and every news organization a copy so they don't keep screwing this up.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on September 5, 2019
★★★★★ 3
Please use a larger font
Format: Hardcover
Over 60 and sometimes have a difficult time with too small print? My advise .. either read it on an ebook or skip this one.
I read the first chapter despite the small font size that made it a little too difficult to read. While I found it informative and well worth reading I'm probably not going to read anymore and return it to the library. Mass market paperback books with small print I can understand. Hardback non-fiction books (which are generally read by an older crowd I suspect) make no sense to me.
5 stars for the content I read. 1 star (generously) for the font size.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on January 6, 2020
★★★★★ 5
Great review and analysis of a law that underpins the Internet
Format: Kindle
This book provides a detailed history of how section 230 if the Communications Decency Act came to be, its importance and its problems as the industry of the Internet matures. While it is ultimately a defense of that law, it is an eyes wide open look at it as well. It is not a prophet's telling of what to do, but instead an informative read that gives the reader an ability to assess what might be done to address the issues 230 raises.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on October 9, 2019
★★★★★ 5
Dealing with complexity
Format: Kindle
Section 230 is a simple effort to govern what must be the innovation of our time. This account is a great effort to explain the accomplishments and challenges that simple can allow.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on December 27, 2022
recommand products
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases | CNS Drugs
27.51
Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease
27.86
Who Should Explore GLP-1 Shots from BodyLogicMD?
27.93
GLP-1
29.17
Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease
28.35